Crinetics Pharmaceuticals
CRNX
203 hedge funds and large institutions have $3.76B invested in Crinetics Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 78 increasing their positions, 55 reducing their positions, and 28 closing their positions.
79% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 28
48% more capital invested
Capital invested by funds: $2.54B → $3.76B (+$1.23B)
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
42% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 55
21% more call options, than puts
Call options by funds: $34.1M | Put options by funds: $28.1M
12% more funds holding
Funds holding: 181 → 203 (+22)
3.54% less ownership
Funds ownership: 106.74% → 103.2% (-3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$83.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$60M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$56.1M |
| 4 |
AG
Artal Group
Luxembourg
|
+$54.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$26.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$18.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$16M |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$14.1M |
| 5 |
State Street
Boston,
Massachusetts
|
-$12.1M |
CRNX Hedge Fund Activity: Q1 2024 in Review
203 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2024, worth a combined $3.76B — up 48% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new CRNX positions and 28 closed out — a net gain of 22 holders — while 78 added to existing stakes and 55 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $83.8M. The largest seller was Morgan Stanley, cutting an estimated $26.8M.
- 203 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2024, up from 181 in Q4 2023.
- Funds reported $3.76B of Crinetics Pharmaceuticals stock for Q1 2024, up 48% quarter-over-quarter.
- 50 funds opened new Crinetics Pharmaceuticals positions in Q1 2024 and 28 closed out, a net change of +22 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2024 was EcoR1 Capital, an estimated $83.8M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $26.8M sold.
Based on aggregated 13F filings for Q1 2024.